NCT07148180: A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Sponsor: Jacqueline Garcia, MD. Phase: PHASE1. Conditions: Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers